
  
    
      
        
        What_WP is_VBZ the_DT level_NN of_IN medical_JJ evidence_NN that_WDT should_MD be_VB used_VBN to_TO inform_VB medical_JJ practice_NN ?_. At_IN
        the_DT bottom_NN of_IN the_DT hierarchy_NN of_IN evidence_NN are_VBP anecdotes_NNS ,_, expert_NN opinion_NN ,_, case_NN reports_NNS ,_, and_CC
        case_NN series_NN ,_, and_CC at_IN the_DT top_NN is_VBZ the_DT systematic_JJ review_NN of_IN published_VBN (_( and_CC sometimes_RB
        unpublished_JJ )_) evidence_NN ._. By_IN necessity_NN ,_, systematic_JJ reviews_NNS come_VBP many_JJ years_NNS after_IN hypotheses_NNS
        are_VBP first_RB raised_VBN ,_, and_CC in_IN the_DT interim_JJ recommendations_NNS for_IN practice_NN may_MD sway_VB back_RB and_CC forth_RB ._.
        One_CD example_NN of_IN this_DT is_VBZ the_DT debate_NN over_IN the_DT role_NN of_IN uric_JJ acid_NN in_IN heart_NN disease_NN ,_, which_WDT has_VBZ
        been_VBN going_VBG on_IN for_IN more_JJR than_IN 50_CD years_NNS ._. It_PRP started_VBD with_IN a_DT paper_NN published_VBN in_IN 1951_CD in_IN the_DT 
        Annals_NNP of_IN Internal_NNP Medicine_NNP that_WDT found_VBD higher_JJR serum_NN uric_JJ acid_NN
        concentrations_NNS in_IN patients_NNS with_IN coronary_JJ heart_NN disease_NN (_( CHD_NNP )_) compared_VBN with_IN controls_NNS ._. Since_IN
        then_RB ,_, measurement_NN of_IN serum_NN uric_JJ acid_NN has_VBZ been_VBN suggested_VBN as_IN a_DT predictor_NN of_IN CHD_NNP ._. But_CC many_JJ of_IN
        the_DT studies_NNS on_IN serum_NN uric_JJ acid_NN are_VBP epidemiologic_JJ studies—somewhere_NN in_IN the_DT middle_NN of_IN the_DT
        hierarchy_NN of_IN evidence—and_NN have_VBP come_VBN to_TO different_JJ conclusions_NNS about_IN how_WRB useful_JJ measurement_NN
        of_IN uric_JJ acid_NN is_VBZ ._.
        Dissecting_NNP out_RP the_DT role_NN of_IN uric_JJ acid_NN is_VBZ further_RBR complicated_VBN by_IN three_CD things_NNS :_: high_JJ levels_NNS
        of_IN uric_JJ acid_NN are_VBP associated_VBN with_IN hypertension_NN and_CC being_VBG overweight_NN (_( other_JJ risk_NN factors_NNS for_IN
        CHD_NNP )_) ;_: levels_NNS of_IN uric_JJ acid_NN can_MD be_VB altered_VBN by_IN drugs_NNS such_JJ as_IN diuretics_NNS that_IN people_NNS with_IN CHD_NNP
        often_RB take_VBP ;_: and_CC finally_RB ,_, alteration_NN of_IN renal_JJ function_NN can_MD affect_VB uric_JJ acid_NN levels_NNS ._. Another_DT
        problem_NN is_VBZ the_DT type_NN of_IN studies_NNS that_WDT have_VBP been_VBN used_VBN to_TO address_VB the_DT question_NN of_IN uric_JJ acid_NN 's_POS
        role_NN in_IN CHD_NNP ._. Retrospective_NNP studies_NNS may_MD be_VB unable_JJ to_TO control_VB adequately_RB for_IN other_JJ risk_NN
        factors—hence_NN prospective_JJ ,_, ideally_RB population-based_JJ ,_, studies_NNS would_MD be_VB the_DT best_JJS to_TO answer_VB
        the_DT question_NN of_IN whether_IN there_EX really_RB is_VBZ an_DT association_NN between_IN high_JJ uric_JJ acid_NN and_CC CHD_NNP ._.
        In_IN this_DT month_NN 's_POS 
        PLoS_NNP Medicine_NNP ,_, John_NNP Danesh_NNP and_CC colleagues_NNS from_IN the_DT University_NNP of_IN
        Cambridge_NNP ,_, along_IN with_IN investigators_NNS from_IN the_DT Icelandic_NNP Heart_NNP Association_NNP ,_, report_NN the_DT single_JJ
        largest_JJS prospective_JJ study_NN addressing_VBG the_DT role_NN of_IN uric_JJ acid_NN in_IN heart_NN disease_NN ._. Further_RB ,_, their_PRP$
        systematic_JJ review_NN combines_VBZ their_PRP$ findings_NNS with_IN those_DT of_IN 15_CD previously_RB published_VBN prospective_JJ
        studies_NNS of_IN serum_NN uric_JJ acid—_NN 9_CD ,_, 458_CD cases_NNS of_IN CHD_NNP and_CC 155_CD ,_, 084_CD controls_NNS in_IN all_DT ._.
        The_DT paper_NN answers_VBZ the_DT question_NN of_IN the_DT role_NN of_IN uric_JJ acid_NN in_IN prediction_NN of_IN CHD_NNP clearly_RB :_:
        the_DT risk_NN ratio_NN for_IN prediction_NN of_IN disease_NN was_VBD 1_CD ._. 13_CD (_( 1_CD ._. 07_CD –_NN 1_CD ._. 20_CD )_) ,_, but_CC it_PRP was_VBD only_RB 1_CD ._. 02_CD
        (_( 0_CD ._. 91_CD –_NN 1_CD ._. 14_CD )_) in_IN the_DT eight_CD studies_NNS that_WDT had_VBD the_DT most_RBS complete_JJ adjustment_NN for_IN possible_JJ
        confounders_NNS ._. What_WP this_DT paper_NN does_VBZ not_RB do_VB is_VBZ directly_RB address_VB the_DT question_NN of_IN whether_IN or_CC not_RB
        serum_NN uric_JJ acid_NN is_VBZ involved_VBN in_IN causing_VBG CHD_NNP through_IN intermediates_NNS ;_: however_RB ,_, it_PRP does_VBZ suggest_VB
        that_DT serum_NN uric_JJ acid_NN levels_NNS are_VBP unlikely_JJ to_TO be_VB a_DT major_JJ determinant_NN of_IN CHD_NNP ._.
        Where_WRB does_VBZ such_JJ a_DT result_NN leave_NN patients_NNS ?_. Well_RB ,_, it_PRP is_VBZ likely_JJ that_IN improving_VBG diet_NN ,_, losing_VBG
        weight_NN ,_, and_CC controlling_VBG blood_NN pressure_NN may_MD all_DT contribute_VBP to_TO reducing_VBG both_DT one_CD 's_POS risk_NN of_IN
        CHD_NNP and_CC one_CD 's_POS serum_NN levels_NNS of_IN uric_JJ acid_NN ._. The_DT role_NN of_IN uric_JJ acid_NN in_IN CHD_NNP is_VBZ now_RB likely_JJ to_TO be_VB
        of_IN interest_NN only_RB to_TO those_DT studying_VBG basic_JJ science_NN ;_: for_IN now_RB ,_, the_DT clinical_JJ question_NN seems_VBZ
        closed_VBN ._.
      
    
  
